Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 62 for “"CYP2B6"”.
-
CYP2A6 and CYP2B6: Sources of Variation and their Role in Nicotine Metabolism
… CYP2A6 (80-90%), with a minor possible role for CYP2B6. Substantial interindividual variability is observed in the rate of nicotine’s inactivation to cotinine and this variation contributes to differences in smoking behaviors (e.g. cigarette consumption). Twin studies suggest an important genetic …
-
GENETIC VARIATIONS OF CYP2B6 ENZYME AND THE RESPONSE TO MEPERIDINE IN ORAL SEDATION
… study was to determine the relationship of the CYP2B6 genotype to the clinical response to meperidine in pediatric dental patients. Methods: Forty-nine patients, ASA I/ II, 41–101 months old, received an oral sedative regimen containing meperidine for dental treatment. The North Carolina …
-
GENETIC VARIATIONS OF CYP2B6 ENZYME AND THE RESPONSE TO MEPERIDINE IN ORAL SEDATION
… this study was to determine the relationship of CYP2B6 genotype to the clinical response to meperidine in pediatric dental patients. Methods: Twenty-five patients, ASA I/ II, 45–92 months old, received an oral sedative regimen containing meperidine for dental treatment. The North Carolina …
-
Role of CYP2B6 in Perfluorooctanesulfonic Acid (PFOS)-Induced Toxicity and Non Alcoholic Fatty Liver Disease (NAFLD)
… textiles, and other industrial products. Human CYP2B6 is predominantly expressed in the liver and responsible for metabolizing xeno- and endobiotics. CYP2B is induced by PFOS and high-fat diets in rodents and therefore it was hypothesized that CYP2B contributed to PFOS-induced steatosis. …
-
PFOS Alters Metabolism in the Liver and Skeletal Muscle of CYP2B-Null and Humanized CYP2B6-Transgenic Mice
… and diabetes. Previously, humanized CYP2B6-transgenic (hCYP2B6-Tg) mice accumulated more PFOS than Cyp2b-null mice and experienced greater mortality; however, the Cyp2b-null mice experienced greater steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS …
-
TOWARDS ELUCIDATING THE MOLECULAR DETERMINANTS OF EFAVIRENZ METABOLISM BY CYTOCHROME P450 2B6
The polymorphic enzyme cytochrome P450 2B6 (CYP2B6) participates in the metabolism of many clinically relevant drugs. Among these drugs is the anti-HIV drug efavirenz (EFV). In individuals with low activity CYP2B6 phenotypes, EFV plasma levels can be elevated, a fact that is troublesome given the …
-
Mechanisms and quantitative prediction of Efavirenz metabolism, pharmacogenetics and drug interactions
… 2B6, a number of clinical studies found that the CYP2B6*6 allele is significantly associated with higher efavirenz exposure and/or adverse reactions. However, the mechanism of reduced efavirenz metabolism by this genetic variant is not fully understood and whether this variant exhibits …
-
Exploring the role of mu opioid receptor (OPRM1) and CYP2B6 gene variations for methadone pharmacogenomics. Can these variations be used to advance toxicological interpretation post-mortem?.
… the relationship between methadone toxicity and CYP2B6 and mu (μ) opioid receptor (OPRM1) single nucleotide polymorphisms (SNPs). Using SNP genotyping, the association between OPRM1 A118G and CYP2B6 T750C, G516T, and A785G variations and post-mortem methadone concentrations were investigated. The …
-
Role of cytochrome P450 2B6 polymorphisms in unexpected methadone death
… is stereoselectively metabolized in the liver by CYP2B6. The purpose of this study was to determine if one or more SNPs located within the CYP2B6 gene contributes to a poor metabolizer phenotype for unexpected methadone deaths. A study cohort was obtained from the WV and KY Offices of the Chief …
-
Impact des polymorphismes génétiques du cytochrome P450 2B6 sur les concentrations plasmatiques de l’EFV et de la NVP chez les patients infectés par le virus VIH-1 au Rwanda
… variabilité génétique du cytochrome P450 2B6 (CYP2B6). Les objectifs de ce travailde thèse ont consisté (i) à identifier de nouveaux polymorphismes ponctuels (SNP) au niveau du gène CYP2B6,dans la population rwandaise (ii) de caractériser leurs effets sur l’activité enzymatique in vitro et in …
-
Die Bedeutung genetischer Polymorphismen im Enzym Cytochrom P450 2B6 für Pharmakokinetik und Wirkung des Antidepressivums Bupropion
… wird metabolisiert durch das Cytochrom P450 2B6 (CYP2B6). Wir untersuchten die Auswirkungen genetischer Polymorphismen des CYP2B6 auf die Pharmakokinetik von Bupropion. Die Pharmakokinetik von Bupropion wurde nach oraler Gabe von 150 mg Bupropion an 121 gesunden, freiwilligen, männlichen Probanden …
-
Role of CYP2B in Unsaturated Fatty Acid Metabolism, Obesity, and Non-Alcoholic Fatty Liver Disease
… human CYPs. Therefore, PUFA metabolites of human CYP2B6 were identified from CYP2B6 containing baculosomes by LC-MS/MS. Results indicate human CYP2B6 primarily metabolizes PUFAs in the 9- and 13- positions with a preference for -linolenic acid in vitro. To increase relevance to humans, we …
-
Γονίδια αποτοξικοποίησης στη διερεύνηση της προδιάθεσης της οξείας μυελογενούς λευχαιμίας
… παράγοντες στην ΟΜΛ. Το ένζυμο αποτοξικοποίησης CYP2B6 έχει σημαντικό ρόλο στο μεταβολισμό ξενοβιοτικών, προστατεύοντας το κύτταρο από μεταλλάξεις που μπορεί να οδηγήσουν σε χρωμοσωματικές αλλοιώσεις και καρκίνο. Το γονίδιο CYP2B6 παρουσιάζει γενετικό πολυμορφισμό τύπου SNP (single nucleotide …
-
Characterizing bupropion metabolism, pharmacokinetics and drug-drug interaction liability
… is also the preferred sensitive in vivo CYP2B6 substrate recommended by the FDA (U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2012). Efavirenz, the only other CYP2B6 sensitive substrate, is a time dependent inhibitor (Bumpus et al., 2006) and inducer …
-
Selectivity and Mechanisms of Human Cytochrome P450 Inhibition by Chlormethiazole
… inhibition of cytochrome P450 2E1 (CYP2E1), 2B6 (CYP2B6), and 3A4/5 (CYP3A4/5) by CMZ. CMZ elicits a clinically significant drug-drug interaction (DDI) with chlorzoxazone due to potent CYP2E1 inhibition in vivo. It has been reported that chlormethiazole is a time-dependent inhibitor of CYP2E1 and …
-
The Effects of Ethanol and Nicotine on Hepatic and Brain CYP2 Family Enzymes in African Green Monkeys
… on hepatic and/or brain levels of CYP2E1, CYP2B6 and CYP2A6 in African green monkeys. Monkeys were randomized into four groups (N = 10/group): an ethanol-only group, a nicotine-only group, an ethanol + nicotine group and a control (no drug) group. Ethanol (10% ethanol in sucrose solution) …
-
Metabolic Dysfunction Caused by Dietary Oxylipins and the Environmental Toxicant PFOS
… disease. A liver enzyme, Cytochrome P450 2B6 (CYP2B6) is an anti-obesity enzyme that produced several omega-3 and omega-6 fatty acid metabolites that could contribute to metabolic diseases such as fatty liver disease. Two of these metabolites, 9-HODE and 9-HOTrE, may be associated with fatty …
-
Κυτταρογενετική και μοριακή μελέτη ασθενών με πρωτοπαθή και δευτεροπαθή οξεία μυελογενή λευχαιμία
… polymorphisms of the detoxification genes CYP2B6 (G516T, C777A, A785G), GSTP1 (A313G) and DNA repair genes RAD51 (G135C), XPD23 (A23927C) and LIG4 (C26T) in the development of AML. We also investigated the methylation status of the promoter of GSTP1 gene in the development of AML. The study …
-
Pharmacogenetics of ketamine metabolism and immunopharmacology of ketamine
… norketamine, by two hepatic CYP enzymes: CYP2B6 and CYP3A4, whose expression and catalytic activities show vary large variability in humans due to genetic and environmental influences. Therefore, it is logical that the variability in these enzymes contributes to the variability in ketamine …
Page 1 of 4